Search research articles
Contact Us
Filters
Showing results (1-10 of 46) with videos related to
Page
of 5
Sort By:
Neurodegenerative Disease Management
|
February 7, 2014
IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation
Talene A Yacoubian
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 18, 2025
It Takes Guts: A Novel Model for Gut-to-Brain Propagation of Alpha-Synuclein and Tau
Kasandra Scholz, Talene A Yacoubian
Trends in Pharmacological Sciences
|
May 14, 2020
007 (x2)-3-3: 14-3-3 Targeted Compounds as Double Agents
Mary Gannon, Talene A Yacoubian
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 4, 2017
Disparate genes come together: Spatial and genetic screens point to disruptions in vesicle trafficking and mRNA metabolism in synucleinopathies
Rachel Underwood, Talene A Yacoubian
Disease Models & Mechanisms
|
April 30, 2010
Target validation: the Parkinson disease perspective
David G Standaert, Talene A Yacoubian
Biochimica Et Biophysica Acta
|
October 22, 2008
Targets for neuroprotection in Parkinson's disease
Talene A Yacoubian, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 8, 2014
Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegeneration
Talene A Yacoubian, David G Standaert
Biorxiv : the Preprint Server for Biology
|
July 3, 2023
14-3-3 phosphorylation inhibits 14-3-3θ's ability to regulate LRRK2 kinase activity
Rudradip Pattanayak, Chad M Petit, Talene A Yacoubian
Plos One
|
July 30, 2011
14-3-3theta protects against neurotoxicity in a cellular Parkinson's disease model through inhibition of the apoptotic factor Bax
Sunny R Slone, Mathieu Lesort, Talene A Yacoubian
Journal of Neurochemistry
|
November 25, 2010
A neuroprotective role for angiogenin in models of Parkinson's disease
Trent U Steidinger, David G Standaert, Talene A Yacoubian
Page
of 5
Search research articles
Search
Showing results (1-10 of 46) with videos related to
Sort By:
Page
of 5
Neurodegenerative Disease Management
|
February 7, 2014
IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation
Talene A Yacoubian
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 18, 2025
It Takes Guts: A Novel Model for Gut-to-Brain Propagation of Alpha-Synuclein and Tau
Kasandra Scholz, Talene A Yacoubian
Trends in Pharmacological Sciences
|
May 14, 2020
007 (x2)-3-3: 14-3-3 Targeted Compounds as Double Agents
Mary Gannon, Talene A Yacoubian
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 4, 2017
Disparate genes come together: Spatial and genetic screens point to disruptions in vesicle trafficking and mRNA metabolism in synucleinopathies
Rachel Underwood, Talene A Yacoubian
Disease Models & Mechanisms
|
April 30, 2010
Target validation: the Parkinson disease perspective
David G Standaert, Talene A Yacoubian
Biochimica Et Biophysica Acta
|
October 22, 2008
Targets for neuroprotection in Parkinson's disease
Talene A Yacoubian, David G Standaert
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 8, 2014
Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegeneration
Talene A Yacoubian, David G Standaert
Biorxiv : the Preprint Server for Biology
|
July 3, 2023
14-3-3 phosphorylation inhibits 14-3-3θ's ability to regulate LRRK2 kinase activity
Rudradip Pattanayak, Chad M Petit, Talene A Yacoubian
Plos One
|
July 30, 2011
14-3-3theta protects against neurotoxicity in a cellular Parkinson's disease model through inhibition of the apoptotic factor Bax
Sunny R Slone, Mathieu Lesort, Talene A Yacoubian
Journal of Neurochemistry
|
November 25, 2010
A neuroprotective role for angiogenin in models of Parkinson's disease
Trent U Steidinger, David G Standaert, Talene A Yacoubian
Page
of 5